UnitedHealthcare Community Plan

Opioid Products - Maryland
PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826.**
This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance:	Policy #:	Group #:

Is the requested medication □ New or □ Continuation of Therapy? If continuation, list start date: _____
Is this patient currently hospitalized? □ Yes □ No If recently discharged, list discharge date: _____

Section B - Provider Information

First Name:		Last Name:		M.D./D.O.
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information

Medication:	**Strength:**
Directions for use:	**Quantity:**
Diagnosis (Please be specific & provide as much information as possible)**:**	**ICD-10 CODE:**

Is this member pregnant? □ Yes □ No If yes, what is this member's due date? _____

Section D – Previous Medication Trials

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information about this case, if any:

UnitedHealthcare Community Plan

Opioid Products - Maryland
PRIOR AUTHORIZATION REQUEST FORM

Member First name:	Member Last name:	Member DOB:

Clinical and Drug Specific Information

□ Yes □ No	**Does the prescriber attest to ALL of the following: (REQUIRED)**

- **The information provided is true and accurate to the best of their knowledge and they understand that UnitedHealthcare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided.**
- **Patient has been screened for substance abuse/opioid dependence**
- **Pain is moderate to severe and expected to persist for an extended period of time [chronic]** *(Long-acting opioids only)*

Prescriber's Signature: _____ Date:_____

Opioid overdose reversal medications are a covered benefit without prior authorization. CDC guidelines recommend offering naloxone to patients at increased risk of overdose, defined as: history of overdose or substance use disorder, doses > 50 MED/day, or concurrent use with benzodiazepines. Please refer to Preferred Drug Plan for preferred products.

ALL REQUESTS

□ Yes □ No	**Does the patient meet any of the following conditions or care instances?** *(If yes, check all that apply)* □ Cancer diagnosis □ End-of-life care □ Hospice care □ Non-cancer pain □ Palliative care □ Post-surgery □ Sickle cell disease
□ Yes □ No	**Have treatment goals been defined and include estimated duration of treatment?** *If yes, document treatment goals:*
□ Yes □ No	**Has the patient been screened for underlying depression and/or anxiety?**
□ Yes □ No	**If applicable, have any underlying conditions been or will be addressed?**
□ Yes □ No	**Is the patient being discharged from an inpatient facility (inpatient hospital, ambulatory surgery center [ASC], emergency room [ER]) or is this an outpatient request?** *(If yes, check which applies)* □ Outpatient request □ Inpatient discharge request
□ Yes □ No	**For <u>outpatient</u> requests, does the prescriber attest to ALL of the following?** • The prescriber has reviewed controlled substance prescriptions in the prescription drug monitoring program (PDMP) [CRISP] before prescribing opioids. • The patient has/will have random Urine Drug Screens as part of their on-going therapy with opioids. • Naloxone prescription was provided or offered to patient/patient's household. • A Patient-Prescriber Pain Management/Opioid Treatment Agreement/Contract has been signed and is in patient's medical record.
□ Yes □ No	**For <u>inpatient discharge</u> requests, does the prescriber attest to ALL of the following?** • The prescriber has reviewed controlled substance prescriptions in the prescription drug monitoring program (PDMP) [CRISP] before prescribing opioids. • Naloxone prescription was provided or offered to patient/patient's household. • The provider has discussed the risks/benefits associated with opioid use with patient/patient's household. • The patient is exempt from need for a Patient-Prescriber Pain Management/Opioid Treatment Agreement and random urine drug screens (UDS), because he/she is being discharged from the hospital/ASC/ER and opioid treatment prescribed by the discharging provider will be for less than 30 days or the need for further opioid use will be re-evaluated by an outpatient provider within 30 days.
□ Yes □ No	**If the request is for a non-preferred medication, has the patient had a failure, contraindication or intolerance to a trial of at least three preferred short acting opioids?** *(If yes, complete Section D above)*
□ Yes □ No	**Does the patient have a history of failure, contraindication or intolerance to a trial of any of the following?** *(If yes, check all that apply and complete Section D above)* □ Fentanyl transdermal (12, 25, 50, 75, and 100mcg) □ Hydrocodone extended-release capsules (generic Zohydro ER) □ Morphine sulfate controlled release tablets (generic MS Contin) □ Oxymorphone ER non-crush resistant (generic)

UnitedHealthcare Community Plan

Opioid Products - Maryland
PRIOR AUTHORIZATION REQUEST FORM

Member First name:	Member Last name:	Member DOB:

□ Yes □ No	**Does the patient have a history of failure, contraindication or intolerance to a trial of tramadol immediate release (IR)?** *(If yes, complete Section D above)*
□ Yes □ No	**Requests for Tramadol 100mg tablets:** **Is there rationale for needing to use the 100 mg tramadol tablet instead of two 50 mg tramadol tablets?** *If yes, document rationale:*
□ Yes □ No	**Requests for Qdolo:** **Does the patient meet any of the following?** *(If yes, check all that apply)* □ Patient has a history of failure, contraindication or intolerance to a trial of tramadol 50 mg tablets *(If yes, complete Section D above)* □ Patient is unable to swallow a solid dosage form □ Patient utilizes a feeding tube for medication administration
CANCER / SICKLE CELL / HOSPICE RELATED PAIN	
□ Yes □ No	**Is the patient being treated for cancer related pain?** *If yes, list cancer diagnosis:*
□ Yes □ No	**Is the patient established on pain therapy with the requested medication for cancer-related pain, sickle cell pain, or hospice related pain, and the medication is not a new regimen for treatment of cancer-related pain, sickle cell pain, or hospice related pain?** *If yes, list start date:*
NON-CANCER / NON-SICKLE CELL / NON-HOSPICE RELATED PAIN	
□ Yes □ No	**Prior to the start of therapy with the long-acting opioid, has the patient failed an adequate (minimum of 2 week) trial of a short-acting opioid within the last 30 days?** *(If yes, complete Section D above)*
□ Yes □ No	**Is the request for postoperative pain and the patient is already receiving chronic opioid therapy prior to surgery or the postoperative pain is expected to be moderate to severe and persist for an extended period of time?**
□ Yes □ No	**Is the patient being treated for non-neuropathic pain OR neuropathic pain (such as neuralgias, neuropathies, fibromyalgia)?** *(If yes, check which applies)* □ Pain that is non-neuropathic □ Pain that is neuropathic (such as neuralgias, neuropathies, fibromyalgia)
□ Yes □ No	**For neuropathic pain requests, unless it is contraindicated, has the patient exhibited an inadequate response to 8 weeks of treatment with gabapentin titrated to a therapeutic dose?** *(If yes, complete Section D above)* □ Check box if Gabapentin is contraindicated
□ Yes □ No	**For neuropathic pain requests, unless it is contraindicated, has the patient exhibited an inadequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose?** *(If yes, complete Section D above)* □ Check box if tricyclic antidepressant is contraindicated
QUANTITY LIMIT & EXCEEDING 90 MME CUMULATIVE THRESHOLD ***(continued on next page)***	
□ Yes □ No	**Can the requested dose be achieved by moving to a higher strength of the product?** *If yes, list reasoning for not switching:*
□ Yes □ No	**Is the requested dose within FDA (Food and Drug Administration) maximum dose per day, where an FDA maximum dose per day exists (see table on page below)?**
□ Yes □ No	**Has the patient tried and failed non-opioid pain medications?** *(If yes, complete Section D above)*
□ Yes □ No	**Have opioid medication doses of less than 90 MME been tried and did not adequately control pain?** *(If yes, complete Section D above)*

UnitedHealthcare Community Plan

Opioid Products - Maryland
PRIOR AUTHORIZATION REQUEST FORM

Member First name:	Member Last name:	Member DOB:

Please note the plan's quantity limits:

Active Ingredient	FDA Label Max Daily Doses	90 MME Equivalent (mg/day) (non treatment naïve)
Morphine	None	90mg
Morphine and naltrexone	None	90mg
Hydromorphone	None	22.5mg
Fentanyl transdermal, mcg/hr	None	37.5 mcg/hr
Hydrocodone	None	90mg
Methadone	None	Conversion factor is variable based upon dose
Tapentadol	600mg IR products 500mg ER products	225mg
Oxymorphone	None	30mg
Oxycodone	Xtampza Only =288mg	60mg
Codeine	360mg	600mg
Pentazocine	None	243mg
Tramadol	400mg IR products 300mg ER products	900mg
Meperidine	600mg	900mg
Butorphanol	None	12.8mg
Opium	4 suppositories/day Deodorized Tincture: 24mg/day Camphorated Tincture: 16mg/day	90mg
Acetaminophen	4g/day	N/A
Aspirin	2080mg/day	N/A
Ibuprofen	3200mg/day	N/A
Benzhydrocodone	None	73.77mg
Levorphanol	None	8.18mg

NEW TO THERAPY FOR SHORT ACTING OPIATES ONLY	
□ **Yes** □ **No**	**Does the patient have any of the following?** *(If yes, check which applies)* □ Traumatic injury □ Post-surgical procedures, excluding dental procedures □ Prescriber attests that the patient has received an opioid within the past 60 days
□ **Yes** □ **No**	**Does the prescriber attests to both of the following?** *(If yes, check which applies)* □ The information provided is true and accurate to the best of their knowledge and they understand that United HealthCare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided. □ If requested for traumatic injury or post-surgical procedure, prescriber attests that based on injury or surgical procedure performed the member requires greater than a 7 day supply for patients 20 years and older or greater than a 3 day supply for patients under the age of 20 years of short-acting opioid to adequately control pain.
CONTINUATION OF THERAPY	
□ **Yes** □ **No**	**Has the patient demonstrated meaningful improvement in pain and function when assessed against treatment goals?** *If yes, list improvement in function or pain score improvement:*
□ **Yes** □ **No**	**Has rationale been identified for not tapering and discontinuing opioid if treatment goals are not met?** *If yes, document rationale:*

Physician Signature: _____ **Date:** _____